Overview
- A securities class action captioned Apitz‑Grossman v. Embecta Corp., No. 26‑cv‑07217, is pending in the U.S. District Court for the District of New Jersey and accuses senior executives of violating Sections 10(b), 20(a) and SEC Rule 10b‑5.
- The complaint traces the damage to Embecta’s May 5, 2026 disclosure that Q2 results missed guidance, cited share loss in the pen‑needle category mostly to a single customer, reported overall retail‑channel softness and cut the quarterly dividend.
- That May 5 announcement coincided with a roughly $5.35 per share decline, a 57.8% drop from May 4 to May 5, 2026, and is the core event plaintiffs use to calculate investor losses.
- Multiple plaintiff law firms have filed notices and are soliciting investors to join or seek lead‑plaintiff status and investors have until August 17, 2026 to move for appointment; no class has been certified and litigation is at an early procedural stage.
- The case will turn on proof of what company executives knew or recklessly ignored about customer concentration and market softness and could affect investor recoveries, corporate governance and how medical‑device firms disclose product‑line risks.